Devices, assemblies, and kits are disclosed for separating and/or metering a plasma sample from a patient's liquid test sample. Also disclosed are methods of producing and using same.

Devices, assemblies, and kits are disclosed for separating and/or metering a plasma sample from a patient's liquid test sample. Also disclosed are methods of producing and using same.

An inflammatory marker is calculated using a nonlinear function including, as variables, a parameter associated with an erythrocyte aggregation and another parameter associated with an erythrocyte density. The parameter associated with the erythrocyte aggregation is calculated based on a syllectogram measured from a blood specimen. The parameter associated with the erythrocyte density is measured from the blood specimen.

An insert for a holding device for reliably and accurately assessing a small volume of blood in a fluid, such as in a volume of surgical fluid collected during a surgical procedure, is provided. The insert may include a circular shelf having an outside perimeter configured to fit up against an inside perimeter of a holding device. The insert may include a center opening. The insert may include a conically-shaped collection cone disposed in the center opening. The collection cone may include a length, an interior surface comprising a red blood cell flocculant coating, a gradually decreasing perimeter terminating in a bottom apex, and a series of graduated volumetric markings along the length of the collection cone.

An insert for a holding device for reliably and accurately assessing a small volume of blood in a fluid, such as in a volume of surgical fluid collected during a surgical procedure, is provided. The insert may include a circular shelf having an outside perimeter configured to fit up against an inside perimeter of a holding device. The insert may include a center opening. The insert may include a conically-shaped collection cone disposed in the center opening. The collection cone may include a length, an interior surface comprising a red blood cell flocculant coating, a gradually decreasing perimeter terminating in a bottom apex, and a series of graduated volumetric markings along the length of the collection cone.

A polynucleotide comprising a hybrid nucleotide sequence representative of a deletional mutation of the GYPB gene, wherein the hybrid nucleotide sequence representative of a deletional mutation of the GYPB gene has a sequence according to SEQ ID NO 1 or SEQ ID NO 2, or a complementary sequence thereto.

A polynucleotide comprising a hybrid nucleotide sequence representative of a deletional mutation of the GYPB gene, wherein the hybrid nucleotide sequence representative of a deletional mutation of the GYPB gene has a sequence according to SEQ ID NO 1 or SEQ ID NO 2, or a complementary sequence thereto.

Methods for testing a red blood cell (RBC) unit for release for transfusion into a subject are described. The methods allow management of the blood supply by assessing the viability of an RBC unit by its levels of dicarboxylic fatty acids (DFA). The methods include testing an RBC sample from an RBC unit for levels of DFA and discarding the RBC unit or releasing or not releasing the RBC unit for transfusion based on the results.

Methods for testing a red blood cell (RBC) unit for release for transfusion into a subject are described. The methods allow management of the blood supply by assessing the viability of an RBC unit by its levels of dicarboxylic fatty acids (DFA). The methods include testing an RBC sample from an RBC unit for levels of DFA and discarding the RBC unit or releasing or not releasing the RBC unit for transfusion based on the results.

The present disclosure relates to methods for generating blood protein profiles from whole blood, red blood cell enriched blood samples, or red blood cell components. The methods involve the comparison of protein levels before and after incubation with protease inhibitors, or the comparison of protein levels after incubation in the presence and absence of protease inhibitors. The protein profiles are used for monitoring and diagnosing diseases and disorders in subjects including colorectal cancer and preeclampsia.